N-acetyltransferase 2 (NAT2) gene polymorphisms in Parkinson's disease
2006

NAT2 Gene Variations and Parkinson's Disease

Sample size: 367 publication Evidence: moderate

Author Information

Author(s): Borlak Juergen, Reamon-Buettner Stella Marie

Primary Institution: Fraunhofer Institute of Toxicology and Experimental Medicine

Hypothesis

Are N-acetyltransferase 2 (NAT2) gene polymorphisms associated with Parkinson's disease?

Conclusion

The study found little evidence for differences in NAT2 polymorphic acetylation genotypes between Parkinson's disease patients and control subjects.

Supporting Evidence

  • The study analyzed three NAT2 genetic variations associated with slow acetylation.
  • A meta-analysis included data from 10 studies with a total of 1,206 PD patients and 1,619 control subjects.
  • The odds ratio for slow acetylators was found to be marginally significant.

Takeaway

The researchers looked at a gene that might affect Parkinson's disease but didn't find strong evidence that it does.

Methodology

Genotyping of NAT2 variations in 243 healthy controls and 124 PD patients, along with a meta-analysis of 10 studies.

Limitations

The study's findings may not apply to all populations due to the focus on Caucasian individuals.

Participant Demographics

243 healthy unrelated Caucasian control subjects and 124 PD patients.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI 1.12–1.54

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1186/1471-2350-7-30

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication